Safety and efficacy of Pfizer and AstraZeneca COVID-19 vaccines even better than clinical trials predicted
Researchers in the UK and United States have demonstrated the efficacy of one dose of either the Pfizer-BioNTech or Oxford-AstraZeneca vaccine against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a real-world community setting in the UK.
The novel SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a threat to global public health and has now claimed the lives of more than 3.1 million people worldwide.
The large prospective observational study of more than 627,000 individuals found that self-reported infection rates among participants who received either vaccine were significantly lower than among unvaccinated controls.
Updated:
Systemic effects included headache, fatigue, chills and shiver, diarrhoea, fever, arthralgia, myalgia, and nausea.
Share Article
AAA
Covishield vaccine vial at the COVID-19 vaccination centre in Coimbatore on Tuesday April 27, 2021. | Photo Credit: PERIASAMY M
Systemic effects included headache, fatigue, chills and shiver, diarrhoea, fever, arthralgia, myalgia, and nausea.
One in four people experience mild, short lived systemic side effects after receiving the COVID-19 preventive by Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine known as Covishield in India with headache, fatigue and tenderness the most common symptoms, according to a study published in the
Lancet Infectious Diseases journal.
The researchers from King s College London in the U.K. also found that most systemic side effects meaning side effects excluding where the injection took place peaked within the first 24 hours following vaccination and usually lasted 1-2 days.
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
email article
In patients with inflammatory bowel disease (IBD), treatment with infliximab (Remicade) was associated with attenuated immunogenicity to a single dose of either the Pfizer or AstraZeneca COVID-19 vaccine, a large British cohort study found.
Concurrent use of an immunomodulator with infliximab, a tumor necrosis factor (TNF) inhibitor, further reduced immunogenicity to either vaccine, reported Tariq Ahmad, MD, of the Royal Devon and Exeter National Health Service (NHS) Foundation Trust in England, and colleagues. Delayed second dosing should be avoided in patients treated with infliximab, the researchers wrote in
.
Reassuringly, however, vaccination after SARS-CoV-2 infection or after a second dose of vaccine, led to seroconversion in most IBD patients.
Access to COVID-19 vaccines: Global approaches in a global crisis
╳
Abstract
Following the extraordinarily rapid development of COVID‑19 vaccines, immunisation is underway in many OECD countries. However, demand will continue to outstrip supply for some time and currently, distribution is strongly skewed in favour of high-income countries. This both inequitable and inefficient. Directing vaccine to where need is greatest would maximise the number of lives saved and speed bringing the pandemic under control, by slowing transmission and reducing the likelihood of the emergence of viral variants of concern. Governments should therefore act now to accelerate vaccination globally, regardless of international borders, by reallocating supplies to areas of greatest need; continuing the scaling-up of production; ensuring that necessary logistics and health care infrastructure are in place; providing further financial and in-kind support to COVAX; and developing long-term strategies tha